# Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin

> **NCT01006603** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 957 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01006603
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 957 (ACTUAL)
- **Last updated:** 2013-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006603, "Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01006603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*